What are the Historical Developments and Current Growth Metrics of the Biomarker Clinical Phase Outsourcing Services Market?
The biomarker clinical phase outsourcing services market has seen considerable growth due to a variety of factors.
• The biomarker clinical phase outsourcing services market has seen exponential growth in recent years. It is expected to rise from $9.71 billion in 2024 to $11.94 billion in 2025, at a CAGR of 23.0%.
This growth is attributed to government initiatives and funding, increased use of biomarkers in diagnostics, more R&D funding, technological advancements in genomics and imaging, and the rising demand for cancer biomarkers.
What Does Future Hold for The Biomarker Clinical Phase Outsourcing Services Market By 2029?
The biomarker clinical phase outsourcing services market is expected to maintain its strong growth trajectory in upcoming years.
• The biomarker clinical phase outsourcing services market is forecast to grow exponentially, reaching $27.09 billion by 2029, with a CAGR of 22.7%.
This growth is driven by the expanding use of biomarkers in clinical trials, increasing demand for precision medicine, companion diagnostics adoption, and rising demand for personalized medicine. Key trends include advanced trial parameters, diagnostic-focused clinical phases, biomarker technology advancements, government funding, and tech advancements.
What Are The Primary Growth Drivers In The Biomarker Clinical Phase Outsourcing Services Market?
The rising number of clinical trials is likely to fuel the biomarker clinical phase outsourcing services market. Clinical trials, which test new treatments or procedures on human participants, have surged due to advancements in medical research, a rise in chronic diseases, and increased funding. Outsourcing providers bring specialized knowledge in biomarker discovery and analysis, enhancing the quality of clinical trial data. In May 2023, the United States National Library of Medicine reported a growth in registered clinical trials, increasing from 399,499 in 2022 to 437,533 across 221 countries. Consequently, the increase in clinical trials is supporting the biomarker clinical phase outsourcing services market.
What Is The Segmentation Of The Global Biomarker Clinical Phase Outsourcing Services Market?
The biomarker clinical phase outsourcing services market covered in this report is segmented –
1) By Type: Surrogate Endpoints, Predictive Biomarker, Prognostic Biomarker, Safety Biomarker, Other Biomarker Types
2) By Service Type: Biomarker Validation, Biomarker Testing Services, Biomarker Sample Analysis
3) By Therapeutic Area: Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutions
Subsegments:
1) By Surrogate Endpoints: Tumor Marker-Based Endpoints, Imaging-Based Endpoints, Genetic or Genomic Markers
2) By Predictive Biomarker: Genetic Predictive Biomarkers, Protein Predictive Biomarkers, Metabolomic Predictive Biomarkers
3) By Prognostic Biomarker: Cancer Prognostic Biomarkers, Cardiovascular Prognostic Biomarkers, Neurological Prognostic Biomarkers
4) By Safety Biomarker: Toxicity Biomarkers, Adverse Drug Reaction Biomarkers, Drug Interaction Biomarkers
5) By Other Biomarker Types: Inflammation Biomarkers, Infectious Disease Biomarkers, Autoimmune Disease Biomarkers
Pre-Book The Biomarker Clinical Phase Outsourcing Services Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Biomarker Clinical Phase Outsourcing Services Market?
Leading companies in biomarker clinical phase outsourcing services are enhancing their competitive position by advancing high-throughput flow cytometry and ELISpot testing for more accurate and rapid biomarker analysis. In November 2022, Celerion Inc., a US-based biotechnology outsourcing services company, expanded its offerings to include GLP/GCP-compliant molecular and cell biology testing. This expansion improves Celerion's ability to support clients through all stages of drug development, from early clinical research to regulatory submissions, allowing for the production of high-quality data that meets regulatory standards and accelerates new medicine development.
Who Are the Key Players In The Biomarker Clinical Phase Outsourcing Services Market?
Major companies operating in the biomarker clinical phase outsourcing services market are:
• Thermo Fisher Scientific Inc.
• Labcorp Drug Development Inc.
• ICON plc
• Eurofins Scientific SE
• WuXi AppTec Co. Ltd.
• Syneos Health Inc.
• Intertek Group plc
• Charles River Laboratories International Inc.
• Parexel International Corporation
• QIAGEN N.V.
• Medpace Inc.
• Bioclinica Inc.
• Evotec SE
• GenScript Biotech Corporation
• Precision for Medicine Inc.
• BioAgilytix Labs LLC
• Celerion Inc.
• Frontage Laboratories Inc.
• SomaLogic Inc.
• Selvita S.A.
• BioIVT LLC
• Discovery Life Sciences LLC
• Metabolon Inc.
• Caprion Proteomics Inc.
• Canopy Biosciences LLC
What Are The Regional Insights Into The Biomarker Clinical Phase Outsourcing Services Market?
North America was the largest region in the biomarker clinical phase outsourcing services market in 2023. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
